6hon MSN
Promising new therapy developed for most common form of bone cancer in children and young adults
Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...
Scientists at Georgetown University's Lombardi Comprehensive Cancer Center have uncovered a new dual function for a well-known cancer-related protein called ezrin. This finding could potentially open ...
Petrylak, MD, of the Yale School of Medicine notes that bone health is a frequently underappreciated aspect of care for patients with prostate cancer. Because androgen d ...
Scientists at Georgetown University's Lombardi Comprehensive Cancer Center have uncovered a new dual function for a ...
The median overall survival was 38.21 months with radium-223 plus enzalutamide and 32.62 months with enzalutamide alone. For patients with metastatic castration-resistant prostate cancer (mCRPC) with ...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that preliminary results from an investigator-sponsored study evaluating botensilimab (BOT) in combination with balstilimab ...
Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases ...
Bone tuberculosis (TB) is not a rare disease, it is suspected in patients with persistent bone or back pain, said Prof Rajesh Malhotra, head of orthopedics and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results